Evidence map›Paper›PMID 17223204›Full record

ArticleAntiviral research2007

Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice.

Aaron L Olsen, John D Morrey, Donald F Smee, Robert W Sidwell

Open access · greenAbstract read
In one paragraph

Article in Antiviral research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Broad-spectrum drugs against viral agents.International journal of molecular sciences · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Aaron L OlsenInstitute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA. alo@cc.usu.edu
John D Morrey
Donald F Smee
Robert W Sidwell
Utah State University · US

Funding

Vascular stabilization as a broad theraprutic platform for biodefenseU54AI065357 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI BLAIR, CAROL D · 2005 to 2013
$77.5M
ANIMAL MODELS OF HUMAN VIRAL INFECTIONS FOR EVALUATION OF EXPERIMENTAL-266015435N01AI015435 · NIAID · UTAH STATE UNIVERSITY · 2004 to 2004
–
NIAID NIH HHS N01 AI015435NIAID NIH HHS N01-AI-15435NIAID NIH HHS U54 AI065357
6 · The paper itself

Abstract

Changes in the permeability of the blood-brain barrier (BBB) were evaluated in two mouse models of viral encephalitis. The ability of sodium fluorescein (NaFl) to cross the BBB from the serum into the central nervous system was assayed in animals inoculated with virulent strains of either Banzi or Semliki Forest viruses. To test the hypothesis that increases in BBB permeability were associated with poor disease outcome subsequent experiments measured BBB permeability in conjunction with treatment with the interferon inducer Ampligen (poly I:poly C(12)U). A single intraperitoneal injection of Ampligen (1 mg/kg) administered either 24 h or 4-6 h before, but not 24 h after, virus inoculation with Banzi virus provided significant improvements in survival, viral brain titers, weight change and BBB permeability. In comparison, a similar treatment with Ampligen administered either 24 h or 4-6 h before inoculation with Semliki Forest virus was able to significantly improve weight change, and BBB permeability, but only animals receiving Ampligen 4-6 h pre-virus showed a significantly improved mortality. In general, it was found that evaluation of BBB permeability was a more sensitive indicator of disease outcome and the antiviral efficacy Ampligen than either weight change or brain viral titers.

Indexed as

Alphavirus InfectionsAnimalsAntiviral AgentsBlood-Brain BarrierBody WeightBrainCapillary PermeabilityEncephalitis, ViralFemaleFlavivirus InfectionsFluoresceinKidneyLiverMiceMice, Inbred BALB CPoly I-CAntiviral AgentsFluoresceinPoly I-Cpoly(I).poly(c12,U)Poly U

Identifiers

PMID17223204
PMCPMC2040264
OpenAlexW2156367313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.